Not available
Quote | Sol-Gel Technologies Ltd. (NASDAQ:SLGL)
Last: | $0.821 |
---|---|
Change Percent: | -1.75% |
Open: | $0.879 |
Close: | $0.821 |
High: | $0.879 |
Low: | $0.8146 |
Volume: | 7,634 |
Last Trade Date Time: | 07/19/2024 03:00:00 am |
News | Sol-Gel Technologies Ltd. (NASDAQ:SLGL)
2024-07-15 07:31:03 ET More on Sol-Gel Technologies Seeking Alpha’s Quant Rating on Sol-Gel Technologies Historical earnings data for Sol-Gel Technologies Financial information for Sol-Gel Technologies Read the full article on Seeking Alpha For...
NESS ZIONA, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved...
Message Board Posts | Sol-Gel Technologies Ltd. (NASDAQ:SLGL)
Subject | By | Source | When |
---|---|---|---|
By the market reaction, not | midastouch017 | investorshub | 07/27/2021 1:57:44 PM |
Finally the approval The target patient population is big | Amatuer17 | investorshub | 07/27/2021 1:36:58 PM |
Sol-Gel Technologies Provides Update on FDA Review of EPSOLAY | midastouch017 | investorshub | 04/27/2021 2:25:29 PM |
PDUFA Dates | midastouch017 | investorshub | 04/25/2021 6:47:19 AM |
Wow, a year ago today SLGL | midastouch017 | investorshub | 03/12/2021 5:13:52 PM |
News, Short Squeeze, Breakout and More Instantly...
Sol-Gel Technologies Ltd. Company Name:
SLGL Stock Symbol:
NASDAQ Market:
Sol-Gel Technologies Ltd. Website:
NESS ZIONA, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved...
NESS ZIONA, Israel, May 28, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved ...